5月12日电，美国总统特朗普签署关于药品价格的行政命令。

Core Viewpoint - The article reports that President Trump signed an executive order regarding drug prices, indicating a significant policy shift aimed at addressing the cost of pharmaceuticals in the United States [1] Group 1: Executive Order Details - The executive order is focused on reducing drug prices, which has been a critical issue in the healthcare sector [1] - This move is expected to impact pharmaceutical companies and their pricing strategies significantly [1] Group 2: Industry Implications - The order may lead to increased scrutiny of drug pricing practices within the pharmaceutical industry [1] - Companies may need to adjust their pricing models in response to potential regulatory changes stemming from this executive order [1]